

## SCIENTIFIC CURRICULUM

***Last name and name: Rinaldi Francesca***

**Place and date of birth:** Camposampiero (Padua), May 24, 1978

**Residence:** Via del Santo 14/A, 35123 Padua, Italy

**Professional Address:** First Neurology Clinic, University Hospital of Padua, Via Giustiniani 2, 35128 Padua, Italy.

**Telephone number:** +39 0498218149; **Cell phone number:** +393490536382

**Fax number:** +390498212574

**Nationality:** Italian

**Email address:** dr.francesca.rinaldi@gmail.com

### ***Titles of study***

Classical maturity achieved at the High School “Tito Livio” of Padua in July 1997, with vote of 60/60.

Graduated in Medicine and Surgery at the University of Padua, November 7, 2003, with vote 110/110 *cum laude*.

Degree thesis: “Parkinson’s disease: sleep disorders and health related quality of life”.

Qualification as Medical Doctor January 2004.

Specialization in Neurology since June 2004 and specialized in Neurology, January 13, 2009, with vote 70/70 *cum laude*.

Specialization thesis: “Cognitive impairment and Multiple Sclerosis: the pathogenetic role of intracortical lesions”.

### ***Clinical experience***

Elective student in Department of Anatomy in 1999.

Elective student in Internal Medicine (Clinica Medica I) in 2000.

Elective student in Psychiatry (III Servizio Psichiatrico) in 2001.

Elective student in Neurology in 2002/2003.

Elective student at the Intensive Care Unit of the Cardiovascular Research Institute, University of California San Francisco in summer 2002.

House officer in Internal Medicine (Clinica Medica III) in 2003, in Pediatrics in 2003, in Obstetrics and Gynaecology in 2003.

Since June 2004 to December 2008 resident in Neurology, in First Neurology Clinic of the Department of Neurological and Psychiatric Sciences, University of Padua.

***Since January 2009 neurologist in First Neurology Clinic of the Department of Neurological and Psychiatric Sciences, University of Padua.***

### **Clinical activity, didactic and research**

Since 2004 Dr. Francesca Rinaldi has been involved in the clinical (diagnosis and therapy) and MRI follow-up of Multiple Sclerosis patients at the Multiple Sclerosis Centre of Padua – University Hospital of Padua.

#### **International Clinical Trials:**

Over the last ten years, Dr. Rinaldi has played a relevant role (treating or examining neurologist) in many international clinical trials (phase II, phase III, phase IV) on Multiple Sclerosis, according to GCP.

#### **Research activities on Multiple Sclerosis:**

Evaluation of Cortical Grey Matter Pathology in Multiple Sclerosis (MS) by Nuclear Magnetic Resonance, with especial interest in:

- Prevalence, evolution and clinical correlation on Inflammatory Cortical Lesions (ICLs) in MS; in particular correlation of ICLs with cognitive impairment in MS patients.
- Different pattern of regional cortical atrophy in the different forms of MS.

Therapy: analysis of efficacy of disease modulating therapies on cortical pathology.

#### **Meetings and training courses:**

- Training course on Multiple Sclerosis: “The early cortical damage and the neuroprotection”, February 17, 2006/Padova, Italy
- Meeting on “Tysabry Re-dosing Study”, March 4, 2006/London, UK
- Course of Neuro-ophthalmology, October 27, 2006/Legnaro, Italy.
- Interactive Seminars “Multiple Sclerosis”, February 23-24, 2007/Napoli, Italy
- Training course on Natalizumab in relapsing remitting Multiple Sclerosis, March 30, 2007/Padova, Italy.
- Training course on MRI in the management of Multiple Sclerosis patient, September 21, 2007/Padova, Italy
- 23rd congress of the European Committee for Treatment and Research in Multiple Sclerosis –ECTRIMS 2007, October 11-14, 2007/Prague, Czech Republic
- Training course on “Natalizumab in Clinical Practise”, January 25, 2008/Padova, Italy
- Training course in neuroimaging, April 22, 2008/Padova
- 7th TEVA & Sanofi-aventis International Symposium on MS, May 23-24, 2008/Vienna, Austria
- CFTY720D2306 Investigator's Meeting June 5-6, 2008/Monaco, Germany
- World congress on Treatment and Research in Multiple Sclerosis – ACTRIMS +ECTRIMS + LACTRIMS 2008, September 17-20, 2008/Montreal, Canada
- Training course of “Pediatric onset of Multiple Sclerosis”, February 17, 2009/Padova, Italy
- Training course on “Tysabri in Triveneto”, April 17, 2009/Padova, Italy
- The 8° Teva and Sanofi-Aventis International Symposium on MS - Recent advances in MS : Challenging paradigms, May 14-17, 2009/Riga, Lettonia

- Training course in Magnetic Resonance Imaging on Multiple Sclerosis, May 22, 2009/Padova, Italy
- S1P1 Investigator Meeting, May 28-29, 2009/Venice, Italy
- Training course in Multiple Sclerosis, March 5-6, 2009/Gallarate, Italy
- TOP SEMINARS in Multiple Sclerosis, June 4-6, 2009/Baveno, Italy
- XL Congresso della Società Italiana di Neurologia – SIN 2009, November 21-25, 2009/Padova, Italy
- *Stage at Stony Brook University Medical Center, March 8-12, 2010/New York, USA*
- *COGNITION DAY for Multiple Sclerosis, May 24-25, 2010/Taormina, Italy (invited as speaker)*
- TOP SEMINARS in Multiple Sclerosis, May 27-29, 2010/Sorrento, Italy
- The European Committee for Treatment and Research in Multiple Sclerosis – ECTRIMS 2010, October 13-16, 2010/Gothenburg, Sweden
- *Exchange Meeting: “L’esperienza del triveneto nella gestione del paziente SM”, November 12, 2010/Merano, Italy (invited as speaker)*
- *Training course “L’evoluzione dell’approccio al paziente con Sclerosi Multipla: terapie DM e terapie sintomatiche”, March 25, 2011/Villalta di Gazzo Padovano, Italy (invited as speaker)*
- The European Committee for Treatment and Research in Multiple Sclerosis – ECTRIMS 2011, October 19-22, 2011/Amsterdam, Netherland
- *Exchange Meeting: “Aspetti clinici, terapeutici e gestionali della SM: esperienze a confronto”, November 10, 2011/Merano, Italy (invited as speaker)*
- *International MS Physician Summit. Data-Driven Decision Making in MS: Addressing MS Patients Needs Today and Tomorrow, March 24-25, 2012/London, UK (invited as speaker)*
- *Training course on “Massima Risonanza - SM: criteri in evoluzione”, September 19, 2012/Padova, Italy (invited as speaker)*
- The European Committee for Treatment and Research in Multiple Sclerosis – ECTRIMS 2012, October 10-12, 2012/Lyon, France
- *Exchange Meeting: “Aspetti clinici, terapeutici e gestionali della SM: esperienze a confronto”, February 01, 2013/Merano (invited as speaker)*
- *“GREENWICH – SM: confrontarsi sulla terapia, decidere per il paziente”, June 14, 2013/Mestre (invited as speaker)*
- *“PEDIATRICANDO – La sclerosi multipla pediatrica”, September 27, 2013/Padova, Italy (invited as speaker)*
- The European Committee for Treatment and Research in Multiple Sclerosis – ECTRIMS 2013, October 3-5, 2013/Copenhagen, Denmark
- *Advisory Board Biogen – La segmentazione del paziente SM, October 17, 2013/Milano, Italy*
- *Training on Neuronutrition – Nutrizione e SM, April 1, 2014/Padova (invited as speaker)*
- *Advisory Board Biogen – La segmentazione del paziente SM: dalla ricerca di mercato all’applicazione nella comunicazione , May 9, 2014/Milano, Italy*
- *“EVOLUTION: Evoluzione degli standard di cura e del ruolo degli operatori sanitari in SM”, December 5, 2014/Padova, Italy (invited as speaker)*
- *“APERTIS VERBIS”: esperienze in SM a confronto”, December 12, 2014/Merano, Italy (invited as speaker)*
- American Academy of Neurology, April 18-25, 2015/Washington DC, USA
- *“SM 2 steps: due passi nel futuro della SM”, September 11, 2015/Padova, Italy (invited as speaker)*

- ***“APERTIS VERBIS”: terapie in SM a confronto”, December 11, 2015/Merano, Italy (invited as speaker)***
- ***Training course on gender medicine: MS and woman, May 2, 2016/Padova, Italy (invited as speaker)***
- ***“La gestione del paziente con SMRR: focus su efficacia e sicurezza”, May 13, 2016/Padova, Italy (invited as speaker)***
- ***“MUST: A Touching Story”, June 24, 2016/Padova, Italy (invited as speaker)***

## Publications on International Papers:

1. Scaravilli T, Gasparoli E, **Rinaldi F**, Polesello G, Bracco F.  
[Health-related quality of life and sleep disorders in Parkinson’s disease.](#) Neurol. Sci. 2003 Oct; 24(3): 209-10.
2. Calabrese M, Agosta F, **Rinaldi F**, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M.  
[Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.](#) Arch Neurol. 2009 Sep;66(9):1144-50.
3. **Rinaldi F**, Perini P, Calabrese M, Rinaldi L, Gallo P.  
[Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.](#) Mult Scler. 2009 Oct 15.
4. Calabrese M, **Rinaldi F**, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Romualdi C, Rinaldi L, Perini P, Gallo P.  
[Widespread cortical thinning characterizes patients with MS with mild cognitive impairment.](#) Neurology. 2010 Jan 26;74(4):321-8.
5. Calabrese M, Mattisi I, **Rinaldi F**, Favaretto A, Atzori M, Bernardi V, Barachino L, Romualdi C, Rinaldi L, Perini P, Gallo P.  
[Magnetic Resonance Evidence of Cerebellar Cortical Pathology in Multiple Sclerosis.](#) J Neurol Neurosurg Psychiatry. 2010 Apr; 81(4):4010-4.
6. **Rinaldi F**, Rinaldi L, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palu’ G, Gallo P.  
[No evidence of JC-virus reactivation in natalizumab-treated Multiple Sclerosis patients: a 18-month follow-up.](#) J Neurol Neurosurg Psychiatry 2010 Jun.
7. **Rinaldi F**, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P.  
[Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.](#) Neurol Sci. 2010 Jun 10. [Epub ahead of print]
8. **Rinaldi F**, Calabrese M, Grossi P, Puthenparampil M, Perini P, Gallo P.  
[Cortical lesions and cognitive impairment in multiple sclerosis.](#) Neurol Sci. 2010 Jul 16. [Epub ahead of print]
9. Calabrese M, **Rinaldi F**, Grossi P, Mattisi I, Bernardi V, Favaretto A, Perini P, Gallo P. [Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis.](#) Mult Scler. 2010 Jul 29. [Epub ahead of print]
10. Filippi M, Rocca MA, Calabrese M, Sormani MP, **Rinaldi F**, Perini P, Comi G, Gallo P. [Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis.](#) Neurology. 2010 Nov 30; 75: 1988-94.
11. Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, **Rinaldi F**, Perini P, Gallo P.  
[Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.](#) Mult Scler. 2011 Jan 12. [Epub ahead of print]
12. Baracchini C, Perini P, Calabrese M, Causin F, **Rinaldi F**, Gallo P.  
[No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset.](#) Ann Neurol. 2011 Jan;69(1):90-9. doi: 10.1002/ana.22228.
13. Calabrese M, **Rinaldi F**, Grossi P, Gallo P.  
[Cortical pathology and cognitive impairment in multiple sclerosis.](#) Expert Rev Neurother. 2011 Mar;11(3):425-32.
14. **Rinaldi F**, Calabrese M, Mattisi I, Bernardi V, Favaretto A, Perini P, Gallo P.  
[The predictive value of gray matter atrophy in clinically isolated syndromes.](#) Neurology. 2011 May 25. [Epub ahead of print].
15. Baracchini C, Perini P, Causin F, Calabrese M, **Rinaldi F**, Gallo P.  
[Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency.](#) Neurology. 2011 Aug 30; 77(9): 844-50. Epub 2011 Aug 17.
16. Calabrese M, Federle L, Bernardi V, **Rinaldi F**, Favaretto A, Varagnolo MC, Perini P, Plebani M, Gallo P.  
[The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis.](#) Mult Scler. 2011 Aug 25. [Epub ahead of print]

17. Calabrese M, Grossi P, Favaretto A, Romualdi C, Atzori M, **Rinaldi F**, Perini P, Saladini M, Gallo P.  
[Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study.](#) J Neurol Neurosurg Psychiatry. 2011 Sep 2.
18. Calabrese M, **Rinaldi F**, Poretto V, Gallo P.  
[The puzzle of multiple sclerosis: gray matter finds its place.](#) Expert Rev Neurother. 2011 Nov;11(11):1565-8.
19. Calabrese M, **Rinaldi F**, Seppi D, Favaretto A, Squarcina L, Mattisi I, Perini P, Bertoldo A, Gallo P.  
[Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study.](#) Radiology. 2011 Dec;261(3):891-8. Epub 2011 Oct 26.
20. Calabrese M, Seppi D, Romualdi C, **Rinaldi F**, Alessio S, Perini P, Gallo P.  
[Gray Matter Pathology in MS: A 3-Year Longitudinal Study in a Pediatric Population.](#) AJNR Am J Neuroradiol. 2012 Mar 15.
21. **Rinaldi F**, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P.  
[Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.](#) Mult Scler. 2012 May 8. [Epub ahead of print]
22. Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, **Rinaldi F**, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE.  
[Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.](#) J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72.
23. Calabrese M, Oh MS, Favaretto A, **Rinaldi F**, Poretto V, Alessio S, Lee BC, Yu KH, Ma HI, Perini P, Gallo P.  
[No MRI evidence of cortical lesions in neuromyelitis optica.](#) Neurology. 2012 Oct 16;79(16):1671-6. doi: 10.1212/WNL.0b013e31826e9a96. Epub 2012 Sep 19.
24. Centonze D, Rossi S, **Rinaldi F**, Gallo P.  
[Severe relapses under fingolimod treatment prescribed after natalizumab.](#) Neurology. 2012 Oct 3. [Epub ahead of print]
25. Calabrese M, Seppi D, Cocco E, Poretto V, **Rinaldi F**, Perini P, Gallo P.  
[Cortical Pathology in RRMS: Taking a Cue from Four Sisters.](#) Mult Scler Int. 2012;2012:760254. doi: 10.1155/2012/760254. Epub 2012 Sep 27.
26. Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, **Rinaldi F**, Perini P, Gallo P.  
[Cortical lesion load associates with progression of disability in multiple sclerosis.](#) Brain. 2012 Oct;135(Pt 10):2952-61. doi: 10.1093/brain/aws246.
27. Calabrese M, Favaretto A, Poretto V, Romualdi C, **Rinaldi F**, Mattisi I, Morra A, Perini P, Gallo P.  
[Low degree of cortical pathology is associated with benign course of multiple sclerosis.](#) Mult Scler. 2012 Oct 15. [Epub ahead of print]
28. **Rinaldi F**, Seppi D, Calabrese M, Perini P, Gallo P.  
[Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.](#) Mult Scler. 2012 Nov;18(11):1640-3. doi: 10.1177/1352458512464282.
29. Peruzzo D, Castellaro M, Calabrese M, Veronese E, **Rinaldi F**, Bernardi V, Favaretto A, Gallo P, Bertoldo A.  
[Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study.](#) J Cereb Blood Flow Metab. 2012 Dec 19. doi: 10.1038/jcbfm.2012.192. [Epub ahead of print].
30. Ghezzi A, Pozzilli C, Grimaldi L, Moiola L, Brescia-Morra V, Lugaesi A, Lus G, **Rinaldi F**, Rocca M, Trojano M, Bianchi A, Comi G, Filippi M; the Italian MS Study Group.  
[Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.](#) Mult Scler. 2013 Feb 11.
31. Calabrese M, Romualdi C, Poretto V, Favaretto A, Morra A, **Rinaldi F**, Perini P, Gallo P.  
[The changing clinical course of multiple sclerosis: A matter of grey matter.](#) Ann Neurol. 2013 Mar 12. doi: 10.1002/ana.23882.
32. Puthenparampil M, Seppi D, **Rinaldi F**, Federle L, Calabrese M, Perini P, Gallo P; Multiple Sclerosis Epidemiology Veneto Study Group (MuSEV).  
[Increased incidence of multiple sclerosis in the Veneto region, Italy.](#) Mult Scler. 2013 Apr; 19(5): 601-4.
33. Seppi D, Puthenparampil M, Federle L, Ruggero S, Toffanin E, **Rinaldi F**, Perini P, Gallo P.  
[Cerebrospinal fluid IL-1 \$\beta\$  correlates with cortical pathology load in multiple sclerosis at clinical onset.](#) J Neuroimmunol. 2014 May
34. Puthenparampil M, Poggiali D, Causin F, Rolma G, **Rinaldi F**, Perini P, Gallo P.  
[Cortical relapses in multiple sclerosis.](#) Mult Scler. 2015 Mar 19.
35. **Rinaldi F**, Perini P, Atzori M, Favaretto A, Seppi D, Gallo P.  
[Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.](#) Mult Scler Int. 2015;2015:369348 Epub 2015 Feb 23.
36. Favaretto A, Lazzarotto A, Poggiali D, Rolma G, Causin F, **Rinaldi F**, Perini P, Gallo P.  
[MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis.](#) Mult Scler 2015 Jul 10

37. Miant S, Perini P, **Rinaldi F**, Gallo P.  
[A case of relapsing-remitting tumour-like inflammation of the central nervous system.](#) Mult Scler 2015 Nov;  
21 (13)
38. Puthenparampil M, Miant S, Federle L, Zanetta C, Toffanin E, Ruggero S, **Rinaldi F**, Gallo P.  
[Baff is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset.](#) J Neuroimmunol 2016 Aug  
15; 297: 63-7.

I authorize the use of my personal data under the Italian privacy law (D. Lgs 196/2003)

Padova, 16/01/2017

Dr.ssa Francesca Rinaldi

A handwritten signature in black ink, appearing to read 'F. Rinaldi', with a stylized circular mark at the beginning.